Introduction: Sunitinib and everolimus were approved for treatment of progressive PNET based on phase III trial data. However, features that may influence outcome with these antitargets have not been well-established.
Aim(s): To identify possible predictive factors (ECOG, Ki-67, hepatic tumor load, surgery, line of treatment) for PFS in pNET patients (pts) treated with Sunitinib.
Materials and methods: Twenty-two pts treated with Sunitinib 37.5mg/d until progression in a single university hospital between Nov 2010-Nov 2013 were analyzed. Pts had a metastatic, non-functioning G1-2 pNETs.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - Targeted therapies
Presenting Author: PhD Paula J Fonseca
, Carmona A
, Solis M
, Faez L
, Ruiz A
, Rodriguez D
, Sánchez M
, Li W
, Menendez M
, Vieitez J
, Garrido M
To read results and conclusion, please login ...
Further abstracts you may be interested in